Osteoporosis Therapy: Mechanistic Antiresorptives
Pulmonary, Bone, Vitamins and Autocoid Therapeutic Agents
Published Online: 29 JAN 2010
Copyright © 2003 by John Wiley & Sons, Inc. All rights reserved.
Burger's Medicinal Chemistry and Drug Discovery
How to Cite
Dodge, J. A. and Bryant, H. U. 2010. Osteoporosis Therapy: Mechanistic Antiresorptives. Burger's Medicinal Chemistry and Drug Discovery. 711–734.
- Published Online: 29 JAN 2010
Osteoporosis is defined as the thinning of bone resulting from the imbalance between bone resorption and bone formation, the two cellular mechanisms that regulate the remodeling of skeletal tissue. This loss of bone ultimately results in an increased risk of fracture. One therapeutic approach to treating patients with osteoporosis is to inhibit the process of bone resorption. This has been clinically manifested by the development of a number of large and small molecules that include calcitonin, integrin inhibitors, cathepsin K inhibitors, OPG/RANKL inhibitors, bisphosponates, and SERMS. This chapter describes recent advances in the anti-resorptive field with a focus on clinically validated targets and the molecules that have been developed to regulate these pathways.
- Cathepsin K Inhibitors;
- Selective Estrogen Receptor Modulators;